Anemia in Chronic Kidney Disease Professional Survey about Therapeutics and Pipeline Review H1 2017

Anemia in Chronic Kidney Disease

Summary 
Renal anemia is a disease in which the patient has an unusually low count of red blood cells. Renal is a term that means of the kidneys, so anemia is often associated with kidney disease. This type of anemia is caused by a lack of erythropoietin, a protein produced in the kidneys that helps to create red blood cells. Symptoms caused by renal anemia include pale skin and gums, become short of breath, dizziness and inability to think clearly.

Click here for sample report @ http://www.wiseguyreports.com/sample-request/1510562-anemia-in-chronic-kidney-disease-renal-anemia-pipeline-review-h1-2017

Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Anemia in Chronic Kidney Disease (Renal Anemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 12, 8, 1, 1, 6, 1 and 1 respectively.
Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.


  Table of Contents 
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Anemia in Chronic Kidney Disease (Renal Anemia) - Overview
Anemia in Chronic Kidney Disease (Renal Anemia) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Anemia in Chronic Kidney Disease (Renal Anemia) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Anemia in Chronic Kidney Disease (Renal Anemia) - Companies Involved in Therapeutics Development
3SBio Inc
Aevi Genomic Medicine Inc
Akebia Therapeutics Inc
Amgen Inc
Bayer AG     
  .Continued
For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/1510562-anemia-in-chronic-kidney-disease-renal-anemia-pipeline-review-h1-2017
About Us
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
Contact Us:
NORAH TRENT
Partner Relations & Marketing Manager
sales@wiseguyreports.com
www.wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)

Neuropathic Pain in depth study and analysis published, H1 2017

Neuropathic Pain
Summary 
Neuropathic pain, or neuralgia, is a condition in which the sensory system is affected. It is commonly accompanied by tissue injury. The nerve fibres could be damaged resulting in the generation of abnormal signals. Neuropathic pain is also exhibited along with many other diseases. The symptoms might include shooting pain and numbness. Several factors are involved in causing neuropathic pain however there seems to be no specific reason. Trauma, kidney disease, alcoholism, infections, stress etc may lead to painful symptoms. The condition may be controlled by the use of medications and psychological therapies.

Click here for sample report @ http://www.wiseguyreports.com/sample-request/1510558-neuropathic-pain-pipeline-review-h1-2017

Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Neuropathic Pain - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Neuropathic Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Neuropathic Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Neuropathic Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, Preclinical, Discovery and Unknown stages are 1, 6, 24, 29, 1, 117, 27 and 3 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 35 and 1 molecules, respectively.

  Table of Contents 
Table of Contents 2
Introduction 8
Neuropathic Pain - Overview 9
Neuropathic Pain - Therapeutics Development 10
Neuropathic Pain - Therapeutics Assessment 38
Neuropathic Pain - Companies Involved in Therapeutics Development 54
Neuropathic Pain - Drug Profiles 113
Neuropathic Pain - Dormant Projects 430
Neuropathic Pain - Discontinued Products 444
Neuropathic Pain - Product Development Milestones 449
Appendix 460
List of Tables
Number of Products under Development for Neuropathic Pain, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
   
  .Continued
For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/1510558-neuropathic-pain-pipeline-review-h1-2017
About Us
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
Contact Us:
NORAH TRENT
Partner Relations & Marketing Manager
sales@wiseguyreports.com
www.wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)

Graves Diseases in depth study and analysis published, H1 2017

Graves Diseases
Summary 
Graves' disease is an immune system disorder that results in the overproduction of thyroid hormones (hyperthyroidism). Symptoms include anxiety, weight loss, change in menstrual cycles, erectile dysfunction, bulging eyes and irregular heartbeat. Risk factors include family history, age, autoimmune disorders, smoking and pregnancy. Treatment includes anti-thyroid medications, beta blockers and surgery.

Click here for sample report @ http://www.wiseguyreports.com/sample-request/1510563-graves-diseases-pipeline-review-h1-2017

Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Graves Diseases - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Graves Diseases (Hormonal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Graves Diseases (Hormonal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Graves Diseases and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 2 and 1 respectively.
Graves Diseases (Hormonal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

  Table of Contents 
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Graves Diseases - Overview
Graves Diseases - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Graves Diseases - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Graves Diseases - Companies Involved in Therapeutics Development
Apitope International NV
Novartis AG
Omeros Corp
Rodos BioTarget GmbH
Graves Diseases - Drug Profiles
ATXGD-59 - Drug Profile
    
  .Continued
For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/1510563-graves-diseases-pipeline-review-h1-2017
About Us
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
Contact Us:
NORAH TRENT
Partner Relations & Marketing Manager
sales@wiseguyreports.com
www.wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)

Multiple Sclerosis Assessment and Therapeutics Analysis Forecasts To H1 2017

Summary 
Multiple sclerosis (MS) is a potentially debilitating disease in which body's immune system eats away at the protective sheath (myelin) that covers nerves. Damage to myelin causes interference in the communication between brain, spinal cord and other areas of body. Symptoms include numbness or weakness in one or more limbs, double vision or blurring of vision, tingling or pain in parts of body, fatigue and slurred speech. The predisposing factors include age, gender, family history and certain infections.

Click here for sample report @ http://www.wiseguyreports.com/sample-request/1510557-multiple-sclerosis-pipeline-review-h1-2017

Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Multiple Sclerosis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Multiple Sclerosis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Multiple Sclerosis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Multiple Sclerosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 9, 30, 32, 1, 168, 34 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 4, 47 and 2 molecules, respectively.
Multiple Sclerosis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

  Table of Contents 
Table of Contents 2
Introduction 9
Multiple Sclerosis - Overview 10
Multiple Sclerosis - Therapeutics Development 11
Multiple Sclerosis - Therapeutics Assessment 48
Multiple Sclerosis - Companies Involved in Therapeutics Development 70
Multiple Sclerosis - Drug Profiles 160
Multiple Sclerosis - Dormant Projects 746
Multiple Sclerosis - Discontinued Products 763
Multiple Sclerosis - Product Development Milestones 766
Appendix 778
List of Tables
Number of Products under Development for Multiple Sclerosis, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
    
  .Continued
For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/1510557-multiple-sclerosis-pipeline-review-h1-2017
About Us
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
Contact Us:
NORAH TRENT
Partner Relations & Marketing Manager
sales@wiseguyreports.com
www.wiseguyreports.com
Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Tumor Necrosis Factor Receptor Superfamily Member 16 Dynamics, Forecast, Analysis and Supply Demand H1 2017

Tumor Necrosis Factor Receptor Superfamily Member 16
Click here for sample report @ http://www.wiseguyreports.com/sample-request/1473974-tumor-necrosis-factor-receptor-superfamily-member-16-low-affinity-neurotrophin-receptor
Summary 
According to the recently published report 'Tumor Necrosis Factor Receptor Superfamily Member 16 - Pipeline Review, H1 2017'; Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) pipeline Target constitutes close to 5 molecules. Out of which approximately 5 molecules are developed by Companies.
Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) - Tumor necrosis factor receptor superfamily member 16 plays a role in the regulation of the translocation of GLUT4 to the cell surface in adipocytes and skeletal muscle cells in response to insulin, probably by regulating RAB31 activity, and thereby contributes to the regulation of insulin-dependent glucose uptake. Low affinity receptor which can bind to NGF, BDNF, NT-3, and NT-4.

Scope of the Report
- The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR)
- The report reviews Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
 Table of Contents 
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) - Overview
Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low
 .Continued
For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/1473974-tumor-necrosis-factor-receptor-superfamily-member-16-low-affinity-neurotrophin-receptor
About Us
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
Contact Us:
NORAH TRENT
Partner Relations & Marketing Manager
sales@wiseguyreports.com
www.wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)

Tyrosine Protein Kinase Mer to Observe Strong Development by H1 2017

Tyrosine Protein Kinase Mer
Click here for sample report @ http://www.wiseguyreports.com/sample-request/1473973-tyrosine-protein-kinase-mer-proto-oncogene-c-mer-or-receptor-tyrosine
Summary 
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Proto-oncogene tyrosine-protein kinase MER is an enzyme encoded by the MERTK gene. It regulates many physiological processes including cell survival, migration, differentiation, and phagocytosis of apoptotic cells. It plays a role in various processes such as macrophage clearance of apoptotic cells, platelet aggregation, cytoskeleton reorganization and engulfment. Functions in the retinal pigment epithelium (RPE) as a regulator of rod outer segments fragments phagocytosis. It also plays an important role in inhibition of Toll-like receptors (TLRs)-mediated innate immune response by activating STAT1.

Scope of the Report
- The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1)
- The report reviews Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
 Table of Contents 
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Overview
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
  .Continued
For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/1473973-tyrosine-protein-kinase-mer-proto-oncogene-c-mer-or-receptor-tyrosine
About Us
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
Contact Us:
NORAH TRENT
Partner Relations & Marketing Manager
sales@wiseguyreports.com
www.wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)

Top trends in TGF Beta Receptor Type 1 by H1 2017

TGF Beta Receptor Type 1
Click here for sample report @ http://www.wiseguyreports.com/sample-request/1473972-tgf-beta-receptor-type-1-activin-a-receptor-type-ii-like
Summary 
TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) pipeline Target constitutes close to 13 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The latest report TGF Beta Receptor Type 1 - Pipeline Review, H1 2017, outlays comprehensive information on the TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Scope of the Report
- The report provides a snapshot of the global therapeutic landscape for TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30)
- The report reviews TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
 Table of Contents 
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) - Overview
TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes

  .Continued
For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/1473972-tgf-beta-receptor-type-1-activin-a-receptor-type-ii-like
About Us
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
Contact Us:
NORAH TRENT
Partner Relations & Marketing Manager
sales@wiseguyreports.com
www.wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)